fam133 Antibody

What is FAM133A and why is it important for research?

FAM133A (Family with Sequence Similarity 133, Member A) is a protein whose specific functions are still being elucidated in research contexts. Understanding FAM133A expression patterns requires reliable antibodies for detection. The commercially available FAM133A antibodies typically target the N-terminal region (amino acids 36-65) of the human FAM133A protein, making them valuable tools for investigating this protein's expression and localization in various tissues and research models . Research interest in FAM133A stems from its potential involvement in cellular pathways that may be relevant to specific physiological and pathological processes.

What applications are FAM133A antibodies validated for?

FAM133A antibodies are validated primarily for Flow Cytometry (FACS), Western Blotting (WB), and ELISA applications . These complementary techniques provide researchers with a comprehensive approach to studying FAM133A: Western blotting allows for molecular weight confirmation and semi-quantitative analysis, Flow Cytometry enables cellular-level expression assessment, and ELISA provides sensitive quantification options. Each application requires specific optimization parameters including antibody dilution, blocking conditions, and detection methods to achieve optimal signal-to-noise ratios.

What species reactivity can be expected with commercially available FAM133A antibodies?

Most commercial FAM133A antibodies demonstrate reactivity specifically with human samples . This species specificity is critical for experimental design and interpretation, particularly for translational research. The demonstrated human reactivity is based on calculated cross-reactivity profiles that assess sequence homology between species. When planning experiments involving non-human models, researchers should carefully verify cross-reactivity through preliminary validation studies to ensure reliable results.

How should I validate a FAM133A antibody before using it in my experimental system?

Validation of FAM133A antibodies should follow a systematic approach:

• Perform positive and negative control testing using tissues or cell lines with known FAM133A expression levels

• Conduct Western blotting to confirm the antibody detects a band of appropriate molecular weight (~15-20 kDa)

• Implement peptide competition assays to verify binding specificity

• For functional studies, consider knockdown or knockout validation systems to demonstrate antibody specificity

• Perform cross-reactivity testing if working with non-human samples

This validation process ensures that subsequent experimental findings can be reliably attributed to FAM133A detection rather than non-specific binding or cross-reactivity issues .

What are the optimal sample preparation protocols for detecting FAM133A in Western blotting?

For optimal FAM133A detection in Western blotting:

• Use RIPA or NP-40 based lysis buffers supplemented with protease inhibitors

• Include phosphatase inhibitors if investigating post-translational modifications

• Prepare protein samples in reducing conditions (with β-mercaptoethanol or DTT)

• Load adequate protein amounts (typically 20-40 μg of total protein)

• Use 12-15% polyacrylamide gels for optimal resolution of the ~15-20 kDa FAM133A protein

• Transfer to PVDF membranes at lower voltages (25V for 2 hours) to prevent small protein loss

• Block with 5% non-fat milk or BSA in TBST

• Dilute primary FAM133A antibody 1:500-1:3000 and incubate overnight at 4°C

• Use appropriate HRP-conjugated secondary antibodies and develop with enhanced chemiluminescence

This methodological approach enhances detection sensitivity while reducing background and non-specific binding .

What controls should be included when using FAM133A antibodies in flow cytometry experiments?

For rigorous flow cytometry experiments with FAM133A antibodies:

• Include isotype control antibodies (matched to the same host species and immunoglobulin class as the FAM133A antibody)

• Run unstained controls for autofluorescence assessment

• Perform single-color controls for compensation when using multiple fluorophores

• Include negative cell populations known not to express FAM133A

• When possible, include positive controls with verified FAM133A expression

• Consider fixation and permeabilization controls to assess the impact of these treatments

• Use secondary antibody-only controls when using unconjugated primary antibodies

These controls allow for accurate gating strategies and reliable interpretation of FAM133A expression patterns across different cell populations .

What are common issues when using FAM133A antibodies in Western blotting and how can they be resolved?

Common Western blotting issues with FAM133A antibodies and their solutions include:

Systematic optimization of these parameters will improve detection reliability and reproducibility .

How can I improve signal-to-noise ratio when using FAM133A antibodies in immunofluorescence?

To enhance signal-to-noise ratio in immunofluorescence applications:

• Optimize fixation protocols (test both PFA and methanol fixation)

• Extend blocking time (2-3 hours) with higher BSA concentration (3-5%)

• Include 0.1-0.3% Triton X-100 for adequate permeabilization

• Titrate antibody concentration between 1:200-1:800 to determine optimal dilution

• Extend primary antibody incubation to overnight at 4°C

• Implement more stringent washing (5-6 washes, 10 minutes each)

• Use mounting media containing anti-fade compounds

• Optimize microscope acquisition settings (exposure time, gain, offset)

• Consider signal amplification systems for low-abundance detection

These refinements help distinguish specific FAM133A signals from background fluorescence, particularly important for subcellular localization studies .

How can I incorporate FAM133A antibodies in multi-parameter flow cytometry for complex phenotyping?

For advanced multi-parameter flow cytometry incorporating FAM133A:

• Select compatible fluorophores with minimal spectral overlap (consider brightness hierarchy)

• Design panels incorporating surface markers for cell identification followed by intracellular FAM133A staining

• Optimize fixation and permeabilization protocols to preserve both surface epitopes and intracellular FAM133A

• Implement sequential staining approaches (surface markers before permeabilization)

• Perform comprehensive compensation controls including FMOs (Fluorescence Minus One)

• Consider intracellular staining buffers specifically formulated for nuclear/cytoplasmic proteins

• Utilize dimensionality reduction techniques (tSNE, UMAP) for data analysis

• Implement biaxial plotting to examine FAM133A expression relative to other parameters of interest

This approach enables correlation of FAM133A expression with specific cell subsets and activation states in heterogeneous populations .

How can I determine if post-translational modifications affect FAM133A antibody recognition?

To investigate post-translational modification effects on antibody recognition:

• Conduct parallel Western blots with samples treated with:

  • Phosphatase inhibitors vs. phosphatase treatment

  • Deglycosylation enzymes (PNGase F, O-glycosidase)

  • Deubiquitinating enzymes

• Perform immunoprecipitation followed by mass spectrometry to identify specific modifications

• Compare antibody recognition patterns between different antibody clones targeting distinct epitopes

• Utilize phosphorylation-specific or modification-specific antibodies in parallel

• Conduct site-directed mutagenesis of potential modification sites in expression constructs

• Compare antibody recognition following treatment with modification-inducing stimuli

This systematic approach helps determine if antibody epitope recognition is affected by common post-translational modifications that might mask or alter the FAM133A epitope .

How does FAM133A differ from related family members like FAM13A and FAM136A, and what implications does this have for antibody selection?

Despite nomenclature similarities, FAM133A, FAM13A, and FAM136A represent distinct protein families with different functions and expression patterns:

When selecting antibodies, researchers must carefully verify they are targeting the intended family member through sequence verification of the immunogen and validation in appropriate positive control systems. Cross-reactivity testing is essential when studying multiple family members simultaneously .

What approaches should be used when studying FAM133A in relation to metabolic pathways or fat distribution?

While FAM13A (not FAM133A) has established roles in adipocyte differentiation and fat distribution , research on FAM133A's potential roles in metabolism requires:

• Careful antibody selection with verification of specificity against FAM13A to avoid misattribution of findings

• Systematic expression profiling of FAM133A across metabolic tissues (adipose depots, liver, muscle)

• Correlation analyses between FAM133A expression and metabolic parameters

• Loss-of-function and gain-of-function studies specific to FAM133A

• Co-immunoprecipitation experiments to identify interaction partners

• Parallel assessment of FAM133A and FAM13A expression patterns to determine potential functional overlap

• Analysis of regulatory elements controlling FAM133A expression in metabolic contexts

This methodical approach helps distinguish FAM133A's specific roles from those of the better-characterized FAM13A in metabolic pathways .

How can single-cell technologies be incorporated with FAM133A antibodies for advanced tissue analyses?

Integrating FAM133A antibodies with single-cell technologies offers powerful new research capabilities:

• For single-cell mass cytometry (CyTOF):

  • Conjugate FAM133A antibodies with rare earth metals

  • Develop optimized fixation protocols preserving epitope recognition

  • Create comprehensive panels incorporating lineage and functional markers

• For spatial transcriptomics and proteomics:

  • Utilize FAM133A antibodies in multiplex immunofluorescence imaging

  • Perform co-localization studies with transcriptomic readouts

  • Implement image cytometry for quantitative spatial analysis

• For single-cell proteomics:

  • Adapt FAM133A detection for microfluidic platforms

  • Develop nanobody versions for improved penetration and reduced steric hindrance

  • Implement antibody-oligonucleotide conjugates for CITE-seq applications

These emerging approaches enable unprecedented resolution of FAM133A expression patterns at single-cell resolution while preserving spatial context .

What considerations are important when designing FAM133A knockout or knockdown experiments to validate antibody specificity?

When designing FAM133A genetic manipulation experiments:

• For siRNA/shRNA approaches:

  • Design multiple targeting sequences across the FAM133A transcript

  • Include scrambled and non-targeting controls

  • Verify knockdown efficiency by qRT-PCR before antibody validation

  • Consider potential off-target effects through whole transcriptome analysis

• For CRISPR/Cas9 knockout validation:

  • Design multiple guide RNAs targeting early exons

  • Generate clonal cell lines and verify editing by sequencing

  • Assess potential compensatory mechanisms (e.g., upregulation of related family members)

  • Perform rescue experiments to confirm specificity

• For both approaches:

  • Compare multiple commercial FAM133A antibodies targeting different epitopes

  • Include isogenic control cells in all experiments

  • Document complete loss of signal as evidence for antibody specificity

  • Consider potential developmental adaptations in stable knockout systems

These rigorous validation approaches establish definitive evidence for antibody specificity while providing valuable reagents for subsequent functional studies .